Endo appoints Blaise Coleman as chief financial officer
Mr. Coleman has been serving as Endo's Interim Chief Financial Officer since November 22, 2016.
Mr. Coleman joined Endo in January 2015 as Vice President of Corporate Financial Planning & Analysis, and was then promoted to Senior Vice President, Global Finance Operations in November 2015.
Prior to joining Endo, Mr. Coleman held a number of finance leadership roles with AstraZeneca, a global biopharmaceutical company, most recently as the Chief Financial Officer of the AstraZeneca/Bristol-Myers Squibb US Diabetes Alliance.
Prior to that, he was the Head of Finance for the AstraZeneca Global Medicines Development organization based in Mölndal, Sweden.
Mr. Coleman joined AstraZeneca in 2007 as Senior Director Commercial Finance for the US Cardiovascular Business.
He joined AstraZeneca from Centocor, a wholly owned subsidiary of Johnson & Johnson, where he held positions in both the Licenses & Acquisitions and Commercial Finance organizations.
Mr. Coleman's move to Centocor in early 2003 followed 7 years' experience with the global public accounting firm, PricewaterhouseCoopers LLP.
He is a Certified Public Accountant; he holds a Bachelor of Science degree in accounting from Widener University and an M.B.A. from the Fuqua School of Business at Duke University. ■
What to read next
LATEST MOVES FROM Ireland
- Johnson Controls says George Oliver will become chairman
- Fly Leasing appoints Julie Ruehl as CFO
- Venn Life Sciences appoints Christian Bernard Milla as COO
- Allergan appoints Joseph Boccuzi to board
- Roy Dunbar elected to board of Johnson Controls
More inside POST
Rio Tinto H1 profit soars on prices Earnings